Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0F5JZ
|
|||
| Former ID |
DIB020738
|
|||
| Drug Name |
PLX-4720
|
|||
| Synonyms |
PLX 4720; PLX4720 (BRAF inhibitor)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cutaneous melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 1 | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C17H14ClF2N3O3S
|
|||
| Canonical SMILES |
CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)Cl)F
|
|||
| InChI |
1S/C17H14ClF2N3O3S/c1-2-5-27(25,26)23-13-4-3-12(19)14(15(13)20)16(24)11-8-22-17-10(11)6-9(18)7-21-17/h3-4,6-8,23H,2,5H2,1H3,(H,21,22)
|
|||
| InChIKey |
YZDJQTHVDDOVHR-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 918505-84-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
48426216, 49663614, 56072661, 56412907, 84982168, 87557609, 99376103, 99437005, 99443470, 104246213, 124757038, 124898783, 125163842, 125748896, 126584082, 126626061, 126660697, 126728325, 131480707, 135263014, 135685180, 135685181, 135685200, 135686124, 135686125, 135686146, 135686147, 135697775, 135727403, 136367335, 136920368, 137275835, 138197513, 143499492, 152058490, 152237503, 152258869, 152344245, 160647718, 160968084, 162011355, 162202588, 162938881, 163685871, 164764472, 165238065, 172914381, 174561099, 177748742, 178102330
|
|||
| ChEBI ID |
CHEBI:90295
|
|||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist. 2011;16(3):296-309. | |||
| REF 2 | Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011 Oct 30;29(11):1046-51. | |||
| REF 3 | In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003 Jan;9(1):327-37. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.